Dr. Jack Regan reports
LEXAGENE ENTERS COLLABORATION TO INCORPORATE CANCER SEQUENCING TECHNOLOGY INTO A NEW PRODUCT
Lexagene Holdings Inc. has entered into an agreement with the Stanford University School of Medicine. The agreement involves using a targeted sequencing technology developed in the laboratory of Dr. Hanlee Ji, a Stanford associate professor of medicine, in combination with Lexagene's microfluidic instrument. "LexaGene's technology was originally designed for pathogen detection across very large markets -- I am thrilled to report that we are working to expand our technology's capability to include cancer diagnostics and next-generation sequencing," added Dr. Jack Regan, Lexagene's chief executive officer.
About Lexagene Holdings Inc.
Lexagene is a biotechnology company developing the very first easy-to-use fully automated pathogen detection platform that is open access, the LX6. The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.